Technical Analysis for RPRX - Royalty Pharma plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Flat |
| Historical RPRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -1.49% | |
| NR7 | Range Contraction | -1.49% | |
| Inside Day | Range Contraction | -1.49% | |
| Up 3 Days in a Row | Strength | -1.49% | |
| Up 4 Days in a Row | Strength | -1.49% | |
| Up 3 Days in a Row | Strength | -0.79% | |
| Bullish Engulfing | Bullish | 1.25% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Biotechnology Pharmaceutical Drug Development HIV Biopharmaceutical Products Astellas Pharma Abbvie Inc. Biopharmaceutical Industry Drug Development Services Novartis
Biotechnology Pharmaceutical Drug Development HIV Biopharmaceutical Products Astellas Pharma Abbvie Inc. Biopharmaceutical Industry Drug Development Services Novartis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 56.5 |
| 52 Week Low | 42.0 |
| Average Volume | 2,911,646 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 47.63 |
| Average True Range | 3.13 |
| ADX | 0.0 |
| +DI | 27.78 |
| -DI | 16.45 |
| Chandelier Exit (Long, 3 ATRs ) | 47.10 |
| Chandelier Exit (Short, 3 ATRs ) | 51.40 |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | -0.56 |
| MACD Signal Line | -0.44 |
| MACD Histogram | -0.122 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 49.37 | ||||
| Resistance 3 (R3) | 49.50 | 49.06 | 49.08 | ||
| Resistance 2 (R2) | 49.06 | 48.62 | 48.99 | 48.98 | |
| Resistance 1 (R1) | 48.35 | 48.35 | 48.13 | 48.22 | 48.89 |
| Pivot Point | 47.91 | 47.91 | 47.80 | 47.84 | 47.91 |
| Support 1 (S1) | 47.20 | 47.47 | 46.98 | 47.07 | 46.39 |
| Support 2 (S2) | 46.76 | 47.20 | 46.69 | 46.30 | |
| Support 3 (S3) | 46.05 | 46.76 | 46.20 | ||
| Support 4 (S4) | 45.92 |
